Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path

uniQure secured FDA alignment for an accelerated approval Biologics License Application for AMT-130, a gene therapy targeting Huntington’s disease, backed by a $259 million capital raise to fund confirmatory trials and potential commercialization. The accelerated approval pathway provides regulatory clarity but also commits uniQure to a costly, multi-year clinical and operational effort.

This Wire brief sits within Fusion42's coverage of Biotech.